Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
= 132) with IGT or recently diagnosed type 2 diabetes were randomized to 3 months of insulin glargine followed by 9 months of metformin, or 12 months of metformin. Hyperglycemic clamps conducted at baseline, after 12 months of medication, and 3 months after medication withdrawal assessed β-cell function as steady-state and maximal C-peptide responses adjusted for insulin sensitivity. Temporal changes in β-cell function were distinctly different. In youth, β-cell function deteriorated during treatment and after treatment withdrawal, with no differences between treatment groups. In adults, β-cell function improved during treatment, but this was not sustained after treatment withdrawal. The difference in β-cell function outcomes in response to medications in youth versus adults supports a more adverse trajectory of β-cell deterioration in youth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484 · cited 1×
“It is plausible that the pathophysiology of dysglycemia in youth is driven by more severe hepatic and adipose tissue insulin resistance, both of which are potentially related to the obesity and the co-occurrence of fatty liver (21,22).”
BackgroundWeng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · cited 1×
“It is plausible that the pathophysiology of dysglycemia in youth is driven by more severe hepatic and adipose tissue insulin resistance, both of which are potentially related to the obesity and the co-occurrence of fatty liver (21,22).”
BackgroundDiminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483 · cited 1×
“This measure, an estimate of b-cell secretory capacity (17), has previously been suggested to provide an estimate of b-cell mass in animal models and in humans after islet autotransplantation (18).”
ResultThe Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.8.2404 · Cited by 446
TODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2393 · Cited by 288
Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249
Kahn, S. E., Beard, J. C., Schwartz, M. W., Ward, W. K., Ding, H. L., Bergman, R. N., Taborsky, G. J., & Porte, D. (1989) · Diabetes · doi:10.2337/diab.38.5.562 · Cited by 181
The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176 · cited 21×
“Joint models for b-cell response and M/I were fit simultaneously using seemingly unrelated regression techniques (11–13), which provide a 2-DF x2 test of the treatment arm difference in the joint values of b-cell response and M/I between treatment groups within study.”
BackgroundMethodResultInfluential
Cited by
Long-term complications in youth-onset type 2 diabetes
TODAY Study Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100165 · Cited by 546
Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55
TODAY Study Group, Tryggestad, J. B., Kelsey, M. M., Drews, K. L., Chernausek, S. D., Escaname, E. N., Isganaitis, E., Macleish, S., McKay, S., Sprague, J., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1072 · Cited by 48
The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C., & Cercato, C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01337-5 · Cited by 23
Metadata
- Authors
- The RISE Consortium*
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2019-06-09
- Volume
- 68
- Issue
- 8
- Pages
- db190299
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W4237421206
- Cited by
- 72
- References
- 11
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.